{"id":30460,"date":"2024-11-29T17:44:00","date_gmt":"2024-11-29T12:14:00","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=30460"},"modified":"2024-11-29T13:45:40","modified_gmt":"2024-11-29T08:15:40","slug":"radioligand-therapies-reshaping-the-neuroendocrine-tumors-treatment","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/radioligand-therapies-reshaping-the-neuroendocrine-tumors-treatment","title":{"rendered":"From Beta to Alpha Emitters: Radioligand Therapies Reshaping the Neuroendocrine Tumors Treatment Landscape"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-69e083383ad1b\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-69e083383ad1b\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/radioligand-therapies-reshaping-the-neuroendocrine-tumors-treatment\/#The_Rise_of_the_first_and_only_approved_radioligand_therapy_for_GEP-NET_treatment\" >The Rise of the first and only approved radioligand therapy for GEP-NET treatment<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/radioligand-therapies-reshaping-the-neuroendocrine-tumors-treatment\/#Novartis_is_eyeing_LUTATHERAs_broad_adoption_that_covers_its_first-line_usage\" >Novartis is eyeing LUTATHERA\u2019s broad adoption that covers its first-line usage&nbsp;<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/radioligand-therapies-reshaping-the-neuroendocrine-tumors-treatment\/#Beyond_Beta-emitters_radioligand_therapies_What_is_the_Market_opportunity_for_Alpha-emitters_radioligand_therapies\" >Beyond Beta-emitters radioligand therapies: What is the Market opportunity for Alpha-emitters radioligand therapies?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/radioligand-therapies-reshaping-the-neuroendocrine-tumors-treatment\/#Summary\" >Summary&nbsp;<\/a><\/li><\/ul><\/nav><\/div>\n\n<p>Radioligand therapies are rapidly transforming the neuroendocrine tumor treatment landscape, offering new hope to patients and reshaping the market dynamics. This innovative approach, which combines the precision of targeted therapy with the potency of radiation, is gaining significant traction in the oncology community.<\/p>\n\n\n\n<p><strong><em>Keen to learn more? Read the full article to stay informed about the <\/em><\/strong><a href=\"https:\/\/www.delveinsight.com\/blog\/global-neuroendocrine-tumour-market-outlook\"><strong><em>evolving landscape of NET<\/em><\/strong><\/a><strong><em> awareness and treatment!<\/em><\/strong><\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-the-rise-of-the-first-and-only-approved-radioligand-therapy-for-gep-net-treatment\"><span class=\"ez-toc-section\" id=\"The_Rise_of_the_first_and_only_approved_radioligand_therapy_for_GEP-NET_treatment\"><\/span><strong>The Rise of the first and only approved radioligand therapy for GEP-NET treatment<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>LUTATHERA (lutetium Lu 177 dotatate), a beta-emitting radioligand therapy, has been at the forefront of this revolution since its Food and Drug Administration (FDA) approval in 2018 for treating somatostatin receptor-positive (SSTR+) gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in adults. Its success has been remarkable, with sales reaching <strong>USD 605 million<\/strong> in 2023, a <strong>28%<\/strong> increase from the previous year. Novartis is making consistent efforts and is hoping that further label expansion opens up a much anticipated <strong>USD 1 billion<\/strong> market opportunity for LUTATHERA. The recent FDA approval of LUTATHERA for pediatric patients aged 12 and older in April 2024 further expands its reach, making it the first therapy specifically approved for this younger patient population. This milestone underscores the growing confidence in radioligand therapies and their potential to address unmet needs across different age groups.&nbsp;<\/p>\n\n\n\n<p><strong><em>Read the complete <\/em><\/strong><a href=\"https:\/\/www.delveinsight.com\/blog\/lutathera-for-gep-net-treatment\"><strong><em>LUTATHERA\u2019s journey<\/em><\/strong><\/a><strong><em> in treating neuroendocrine tumors (NETs) in our blog<\/em><\/strong><\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-novartis-is-eyeing-lutathera-s-broad-adoption-that-covers-its-first-line-usage-nbsp\"><span class=\"ez-toc-section\" id=\"Novartis_is_eyeing_LUTATHERAs_broad_adoption_that_covers_its_first-line_usage\"><\/span><strong>Novartis is eyeing LUTATHERA\u2019s broad adoption that covers its first-line usage&nbsp;<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>While LUTATHERA has primarily been used as a <a href=\"https:\/\/www.delveinsight.com\/report-store\/neuroendocrine-tumors-net-market\">second-line neuroendocrine tumor treatment<\/a>, there is a growing interest in expanding its use to first-line settings for medium- and high-risk NETs. As per Novartis Q2 quarter report published in July 2024, LUTATHERA\u2019s EU filing accepted for the treatment of newly diagnosed, unresectable or metastatic, well-differentiated (G2 and G3), SSTR+ GEP-NETs in adults, based on NETTER-2 study. NETTER-2 is the first and only positive Phase III trial for a radioligand therapy in the first-line setting, demonstrating the potential of radioligand therapies in earlier lines.&nbsp;&nbsp;<\/p>\n\n\n\n<p>It is worth noting that LUTATHERA technically already has this indication within its US label (SSTR-positive GEP-NETs regardless of a patient\u2019s prior treatment history), thanks to an FDA approval in 2018, but without data to support its widespread use. Since the approval-enabling NETTER-1 trial was conducted in patients with previously treated disease and in those with grade 1 and 2 tumors, the majority of LUTATHERA patients in the real world are getting the drug in the second line. Positive findings from NETTER-2 has highlighted and further strengthed LUTATHERA\u2019s potential in earlier disease settings.&nbsp;<\/p>\n\n\n\n<p>Novartis CEO Vas Narasimhan&#8217;s Statement during an investor call in October 2023 \u2013\u201cThis (data from Phase III NETTER-2 study) would allow us then to add Lutathera on top and really, I think, benefit these patients in really meaningful ways. So we plan to present this data in the first part of next year. And in the case of the US, we wouldn&#8217;t need further label expansion and we plan to really move forward in educating the community on the importance of this data to move LUTATHERA into the frontline setting and in other jurisdictions around the world we&#8217;ll now evaluate how to further expand the label from a regulatory standpoint.\u201d<\/p>\n\n\n\n<p>With LUTATHERA and PLUVICTO, Novartis is working relentlessly to expand its radioligand therapy empire, while simultaneously preparing to take legal action against its rivals. Point Biopharma\/Lantheus has filed what they say is the first generic version of Novartis\u2019 top-selling cancer radionuclide therapy LUTATHERA in the US. Novartis has previously stated that it may take legal action to try to prohibit Lantheus&#8217; generic based on patent infringement; under US law, this may result in a 30-month launch delay.&nbsp;<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-beyond-beta-emitters-radioligand-therapies-what-is-the-market-opportunity-for-alpha-emitters-radioligand-therapies\"><span class=\"ez-toc-section\" id=\"Beyond_Beta-emitters_radioligand_therapies_What_is_the_Market_opportunity_for_Alpha-emitters_radioligand_therapies\"><\/span><strong>Beyond Beta-emitters radioligand therapies: What is the Market opportunity for Alpha-emitters radioligand therapies?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>As the <a href=\"https:\/\/www.delveinsight.com\/report-store\/radioligand-therapies-market-forecast\">field of radioligand therapy<\/a> evolves, there is an exciting shift towards alpha-emitting radioisotopes. Since only beta-emitting radioisotopes are currently approved, companies are now focusing on developing alpha emitters. Alpha particles offer several advantages over beta particles, including:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Higher linear energy transfer (LET), resulting in greater biological damage to cancer cells<\/li>\n\n\n\n<li>Potential to overcome radio- and chemoresistance<\/li>\n\n\n\n<li>More focused cytotoxicity, sparing nearby healthy cells<\/li>\n<\/ul>\n\n\n\n<p>Companies like <strong>ITM Solucin GmbH<\/strong> is working on a non-carrier-added beta-emitter therapy, while companies like<strong> Bristol Myers Squibb\/RayzeBio, Radiomedix\/Orano Med, Perspective Therapeutics<\/strong>, and others are actively advancing alpha-emitter therapies for neuroendocrine tumor treatment.<\/p>\n\n\n\n<p><span id=\"docs-internal-guid-a3f7e290-7fff-e7b2-7b58-36cc1000927d\"><\/span><\/p>\n<div dir=\"ltr\" style=\"margin-left: 0pt;\" align=\"center\">\n<table style=\"border: none; border-collapse: collapse;\"><colgroup><col width=\"105\" \/><col width=\"107\" \/><col width=\"87\" \/><col width=\"132\" \/><col width=\"112\" \/><col width=\"84\" \/><col width=\"89\" \/><\/colgroup>\n<tbody>\n<tr style=\"height: 21.6pt;\">\n<td style=\"vertical-align: middle; background-color: #bfe6ff; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\" colspan=\"7\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: bold; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Comparison of Neuroendocrine Tumors Emerging Drugs<\/span><\/p>\n<\/td>\n<\/tr>\n<tr style=\"height: 21.6pt;\">\n<td style=\"vertical-align: middle; background-color: #f5f5f5; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: bold; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Product<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; background-color: #f5f5f5; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Company<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; background-color: #f5f5f5; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Phase<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; background-color: #f5f5f5; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Indication<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; background-color: #f5f5f5; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">RoA<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; background-color: #f5f5f5; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">MoA<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; background-color: #f5f5f5; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Molecule Type<\/span><\/p>\n<\/td>\n<\/tr>\n<tr style=\"height: 21.6pt;\">\n<td style=\"vertical-align: middle; background-color: #f5f5f5; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: bold; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">ITM-11&nbsp;<\/span><\/p>\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: bold; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">(n.c.a. 177Lu-edotreotide)<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; background-color: #f5f5f5; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">ITM Solucin GmbH<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; background-color: #f5f5f5; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">III<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; background-color: #f5f5f5; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">GEP-NETs<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; background-color: #f5f5f5; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">IV<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; background-color: #f5f5f5; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">SSTR antagonists<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; background-color: #f5f5f5; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Radioligand<\/span><\/p>\n<\/td>\n<\/tr>\n<tr style=\"height: 21.6pt;\">\n<td style=\"vertical-align: middle; background-color: #f5f5f5; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: bold; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">RYZ101&nbsp;<\/span><\/p>\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: bold; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">(Actinium-225 DOTATATE)<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; background-color: #f5f5f5; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Bristol Myers Squibb\/RayzeBio<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; background-color: #f5f5f5; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">III<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; background-color: #f5f5f5; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">GEP-NETs expressing SSTR2 who are refractory to Lu177 SSA treatment<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; background-color: #f5f5f5; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">IV<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; background-color: #f5f5f5; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">SSTR2 inhibitor<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; background-color: #f5f5f5; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Radioligand<\/span><\/p>\n<\/td>\n<\/tr>\n<tr style=\"height: 21.6pt;\">\n<td style=\"vertical-align: middle; background-color: #f5f5f5; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: bold; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">AlphaMedix<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; background-color: #f5f5f5; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Radiomedix\/Orano Med<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; background-color: #f5f5f5; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">II<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; background-color: #f5f5f5; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">PRRT na&iuml;ve and previous PRRT NETs<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; background-color: #f5f5f5; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">IV<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; background-color: #f5f5f5; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Radiolabeled SSTR antagonists<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; background-color: #f5f5f5; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Radioligand<\/span><\/p>\n<\/td>\n<\/tr>\n<tr style=\"height: 21.6pt;\">\n<td style=\"vertical-align: middle; background-color: #f5f5f5; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: bold; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">VMT-&alpha;-NET<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; background-color: #f5f5f5; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Perspective Therapeutics<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; background-color: #f5f5f5; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">I\/II<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; background-color: #f5f5f5; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Unresectable or metastatic somatostatin receptor type 2 -expressing NETs<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; background-color: #f5f5f5; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">IV<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; background-color: #f5f5f5; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">SSTR2 targeting peptide<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; background-color: #f5f5f5; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Radioligand&nbsp;<\/span><\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n\n\n\n<div style=\"height:20px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p>With its ability to selectively destroy cancer cells and even bulky tumors while giving patients an improved quality of life during treatment, Radioligand therapies hold great promise. Increasing global production measures, expanding the use across NETs subtypes, and exploring the potential of new radioisotopes (Actinium-225, Lead-212, and others) will be essential to serve a growing patient population of NETs.&nbsp;<\/p>\n\n\n\n<p>Following the approval of LUTATHERA, there has been a significant shift in focus among pharmaceutical companies toward the development of radioligand therapies. While some players, such as ITM Solucin GmbH, are advancing more refined beta-emitting radioligand therapies, others, including Bristol Myers Squibb\/RayzeBio, Radiomedix\/Orano Med, and Perspective Therapeutics, are exploring the potential of alpha-emitting radioligand therapies. This innovation-driven competition is transforming the therapeutic landscape for NETs.<\/p>\n\n\n\n<p>In 2020, SSAs dominated the US <a href=\"https:\/\/www.delveinsight.com\/report-store\/neuroendocrine-tumors-net-market\">neuroendocrine tumor treatment market<\/a>, accounting for approximately<strong> 50%<\/strong> of the market share. However, by 2034, radioligand therapies are projected to capture the maximum share of the neuroendocrine tumor treatment market, reflecting a paradigm shift driven by their enhanced efficacy and the growing adoption of targeted treatment approaches. This trend underscores the rising prominence of radioligand therapies in redefining neuroendocrine tumor treatment standards.<\/p>\n\n\n\n<p>ITM-11, an emerging radioligand therapy from ITM Solucin GmbH, is anticipated to capture <strong>USD 409 million<\/strong> in the US by 2034. Radiomedix and Orano Med are developing AlphaMedix, the first radioligand therapy to receive breakthrough therapy designation (BTD). AlphaMedix has demonstrated a response rate of <strong>62.5%<\/strong> in GEP-NET patients who had not previously undergone peptide receptor radionuclide therapy (PRRT) with LUTATHERA. AlphaMedix is expected to capture a revenue of <strong>USD 211 million<\/strong> in the US by 2034.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img decoding=\"async\" width=\"1024\" height=\"375\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/11\/29134348\/Neuroendocrine-Tumors-Market-Share-2020-vs.-2034-1024x375.png\" alt=\"Neuroendocrine Tumors Market Share 2020 vs. 2034\" class=\"wp-image-30464\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/11\/29134348\/Neuroendocrine-Tumors-Market-Share-2020-vs.-2034-1024x375.png 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/11\/29134348\/Neuroendocrine-Tumors-Market-Share-2020-vs.-2034-300x110.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/11\/29134348\/Neuroendocrine-Tumors-Market-Share-2020-vs.-2034-150x55.png 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/11\/29134348\/Neuroendocrine-Tumors-Market-Share-2020-vs.-2034-768x281.png 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/11\/29134348\/Neuroendocrine-Tumors-Market-Share-2020-vs.-2034-1536x562.png 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/11\/29134348\/Neuroendocrine-Tumors-Market-Share-2020-vs.-2034-2048x749.png 2048w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Summary\"><\/span><strong>Summary&nbsp;<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The development of innovative therapies, particularly radioligand treatments (both beta-emitting radioligand therapies and alpha-emitter-based therapies) are expected to drive the overall NETs market size. On the other hand, the complex nature of NETs, combined with challenges in drug manufacturing and administration (especially for radiopharmaceuticals), poses significant barriers to market entry and growth. Additionally, the impact of generic competition affects the sales of approved drugs. As research continues and <a href=\"https:\/\/www.delveinsight.com\/report-store\/neuroendocrine-tumors-pipeline-insight\">new neuroendocrine tumor therapies<\/a> emerge, patients with NETs can look forward to more effective, targeted treatments that offer the promise of better outcomes and improved quality of life.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><a href=\"https:\/\/www.delveinsight.com\/report-store\/neuroendocrine-tumors-net-market\"><img decoding=\"async\" width=\"1024\" height=\"194\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/05\/30172806\/Neuroendocrine-Tumors-Market-Outlook-1024x194.png\" alt=\"Neuroendocrine Tumors Market Outlook\" class=\"wp-image-30207\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/05\/30172806\/Neuroendocrine-Tumors-Market-Outlook-1024x194.png 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/05\/30172806\/Neuroendocrine-Tumors-Market-Outlook-300x57.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/05\/30172806\/Neuroendocrine-Tumors-Market-Outlook-150x28.png 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/05\/30172806\/Neuroendocrine-Tumors-Market-Outlook-768x145.png 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/05\/30172806\/Neuroendocrine-Tumors-Market-Outlook-1536x291.png 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/05\/30172806\/Neuroendocrine-Tumors-Market-Outlook.png 1584w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/a><\/figure>\n","protected":false},"excerpt":{"rendered":"<p>Radioligand therapies are rapidly transforming the neuroendocrine tumor treatment landscape, offering new hope to patients and reshaping the market dynamics. This innovative approach, which combines the precision of targeted therapy with the potency of radiation, is gaining significant traction in the oncology community. Keen to learn more? Read the full article to stay informed about [&hellip;]<\/p>\n","protected":false},"author":14,"featured_media":30462,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17],"tags":[18415,22068,1768,2512,2513,2514,2515,22374,22073],"industry":[17225],"therapeutic_areas":[17228],"class_list":["post-30460","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-articles","tag-lutathera","tag-lutathera-market-share","tag-neuroendocrine-tumors","tag-neuroendocrine-tumors-nets","tag-neuroendocrine-tumors-market","tag-neuroendocrine-tumors-market-size","tag-neuroendocrine-tumors-market-trends","tag-neuroendocrine-tumors-treatment","tag-radioligand-therapies","industry-pharmaceutical","therapeutic_areas-oncology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Radioligand Therapy: Changing Neuroendocrine Tumor Treatment<\/title>\n<meta name=\"description\" content=\"Radioligand therapies rapidly transforming neuroendocrine tumor treatment, offering new hope to patients and reshaping market dynamics.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/radioligand-therapies-reshaping-the-neuroendocrine-tumors-treatment\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Radioligand Therapy: Changing Neuroendocrine Tumor Treatment\" \/>\n<meta property=\"og:description\" content=\"Radioligand therapies rapidly transforming neuroendocrine tumor treatment, offering new hope to patients and reshaping market dynamics.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/radioligand-therapies-reshaping-the-neuroendocrine-tumors-treatment\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2024-11-29T12:14:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/11\/29134103\/radioligand-therapies-reshaping-the-neuroendocrine-tumors-treatment.png\" \/>\n\t<meta property=\"og:image:width\" content=\"466\" \/>\n\t<meta property=\"og:image:height\" content=\"284\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Sandeep Joshi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Sandeep Joshi\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Radioligand Therapy: Changing Neuroendocrine Tumor Treatment","description":"Radioligand therapies rapidly transforming neuroendocrine tumor treatment, offering new hope to patients and reshaping market dynamics.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/radioligand-therapies-reshaping-the-neuroendocrine-tumors-treatment","og_locale":"en_US","og_type":"article","og_title":"Radioligand Therapy: Changing Neuroendocrine Tumor Treatment","og_description":"Radioligand therapies rapidly transforming neuroendocrine tumor treatment, offering new hope to patients and reshaping market dynamics.","og_url":"https:\/\/www.delveinsight.com\/blog\/radioligand-therapies-reshaping-the-neuroendocrine-tumors-treatment","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2024-11-29T12:14:00+00:00","og_image":[{"width":466,"height":284,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/11\/29134103\/radioligand-therapies-reshaping-the-neuroendocrine-tumors-treatment.png","type":"image\/png"}],"author":"Sandeep Joshi","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"Sandeep Joshi","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/radioligand-therapies-reshaping-the-neuroendocrine-tumors-treatment","url":"https:\/\/www.delveinsight.com\/blog\/radioligand-therapies-reshaping-the-neuroendocrine-tumors-treatment","name":"Radioligand Therapy: Changing Neuroendocrine Tumor Treatment","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/radioligand-therapies-reshaping-the-neuroendocrine-tumors-treatment#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/radioligand-therapies-reshaping-the-neuroendocrine-tumors-treatment#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/11\/29134103\/radioligand-therapies-reshaping-the-neuroendocrine-tumors-treatment.png","datePublished":"2024-11-29T12:14:00+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a"},"description":"Radioligand therapies rapidly transforming neuroendocrine tumor treatment, offering new hope to patients and reshaping market dynamics.","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/radioligand-therapies-reshaping-the-neuroendocrine-tumors-treatment"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/radioligand-therapies-reshaping-the-neuroendocrine-tumors-treatment#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/11\/29134103\/radioligand-therapies-reshaping-the-neuroendocrine-tumors-treatment.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/11\/29134103\/radioligand-therapies-reshaping-the-neuroendocrine-tumors-treatment.png","width":466,"height":284,"caption":"radioligand-therapies-reshaping-the-neuroendocrine-tumors-treatment"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a","name":"Sandeep Joshi","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","caption":"Sandeep Joshi"},"sameAs":["http:\/\/Delveinsight.com"]}]}},"author_meta":{"display_name":"Sandeep Joshi","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/sjoshidelveinsight-com"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/11\/29134103\/radioligand-therapies-reshaping-the-neuroendocrine-tumors-treatment-300x183.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Articles<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Articles<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Lutathera<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">LUTATHERA Market Share<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Neuroendocrine tumors<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Neuroendocrine Tumors (NETs)<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Neuroendocrine Tumors market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Neuroendocrine Tumors market size<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Neuroendocrine Tumors market trends<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Neuroendocrine Tumors Treatment<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">radioligand therapies<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Lutathera<\/span>","<span class=\"advgb-post-tax-term\">LUTATHERA Market Share<\/span>","<span class=\"advgb-post-tax-term\">Neuroendocrine tumors<\/span>","<span class=\"advgb-post-tax-term\">Neuroendocrine Tumors (NETs)<\/span>","<span class=\"advgb-post-tax-term\">Neuroendocrine Tumors market<\/span>","<span class=\"advgb-post-tax-term\">Neuroendocrine Tumors market size<\/span>","<span class=\"advgb-post-tax-term\">Neuroendocrine Tumors market trends<\/span>","<span class=\"advgb-post-tax-term\">Neuroendocrine Tumors Treatment<\/span>","<span class=\"advgb-post-tax-term\">radioligand therapies<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 1 year ago","modified":"Updated 1 year ago"},"absolute_dates":{"created":"Posted on Nov 29, 2024","modified":"Updated on Nov 29, 2024"},"absolute_dates_time":{"created":"Posted on Nov 29, 2024 5:44 pm","modified":"Updated on Nov 29, 2024 1:45 pm"},"featured_img_caption":"radioligand-therapies-reshaping-the-neuroendocrine-tumors-treatment","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/30460","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=30460"}],"version-history":[{"count":2,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/30460\/revisions"}],"predecessor-version":[{"id":30465,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/30460\/revisions\/30465"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/30462"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=30460"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=30460"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=30460"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=30460"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=30460"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}